Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain

Pain Practice

Volumn 10, Issue 5, 2010, Pages 416-427

  Wild, James E ^a   Grond, Stefan ^b   Kuperwasser, Brigitte ^c   Gilbert, Jane ^d   McCann, Bettyanne ^c   Lange, Bernd ^e   Steup, Achim ^e   Häufel, Thomas ^e   Etropolski, Mila S ^c   Rauschkolb, Christine ^c   Lange, Robert ^e  

^a Upstate Clinical Research Associates   (United States)

^b Lippe Detmold Hospital   (Germany)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e GRÜNENTHAL GMBH   (Germany)

Author keywords

Analgesics; Low back pain; Opioid

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; TAPENTADOL;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FATIGUE; FEMALE; HIP OSTEOARTHRITIS; HIP PAIN; HUMAN; INSOMNIA; KNEE OSTEOARTHRITIS; KNEE PAIN; LONG TERM CARE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SINUSITIS; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 77954810443     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00397.x     Document Type: Article

References (32)

1. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J. 2007;100:1028-1036.
2. Gureje O, Von KM, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. JAMA. 1998;280:147-151.
3. Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther. 2008;15:256-264.
4. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;3: CD006146.
5. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380.
6. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs. 2003;63:17-32.
7. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007;15:957-965.
8. Solomon DH, Avorn J, Wang PS, etal. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum. 2006;55:35-41.
9. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America. 2003;21:699-713.
10. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag. 2003;8:189-194.
11. Tzschentke TM, Christoph T, Kögel B, etal. (-)-(1R, 2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265-276.
12. Tzschentke TM, De Vry J, Terlinden R, etal. Tapentadol HCl. Drugs Future. 2006;31:1053-1061.
13. Smit JW, Oh C, Rengelshausen J, etal. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of open-label, crossover drug-drug interaction studies. Pharmacotherapy. 2010;30:25-34.
14. Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008;2:67-75.
15. Lotsch J, Skarke C, Tegeder I, Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet. 2002;41:31-57.
16. Daniels S, Casson E, Stegmann JU, etal. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25:1551-1561.
17. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765-776.
18. Hartrick C, Van Hove I, Stegmann J-U, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31:260-271.
19. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25:1095-1104.
20. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10:209-217.
21. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253-259.
22. Kaye AD, Banister RE, Hoover JM, Baluch AR, Jacobs S, Shah RV. Chronic pain and ultrarapid opioid detoxification. Pain Pract. 2005;5:33-42.
23. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
24. Adams EH, Chwiecko P, Ace-Wagoner Y, etal. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions-the ACCPT Study. Pain Pract. 2006;6:254-264.
25. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927-934.
26. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther. 2006;28:352-364.
27. Benyamin R, Trescot AM, Datta S, etal. Opioid complications and side effects. Pain Physician. 2008;11(suppl 2):S105-S120.
28. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-R1051.
29. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(suppl 5A):11S-18S.
30. Buynak R, Shapiro D, Okamoto A, Van Hove I, Etropolski M. Efficacy and safety of tapentadol ER for chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2009;10(suppl 1):S50. Abstract 301.
31. Afilalo M, Kuperwasser B, Kelly K, etal. Efficacy and safety of tapentadol extended release (ER) for chronic pain due to osteoarthritis of the knee: results of a phase 3 study. Pain Pract. 2009;9(suppl 1):159. Abstract PB237.
32. Etropolski MS, Shapiro DY, Okamoto A, Rauschkolb-Löffler C, Lange R, Häussler J. Safety and tolerability of tapentadol extended release in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal phase 3 study. Diabetes. 2009;58:A226-A227. Abstract 852-P.